您是记者吗？

了解 ALK

如有任何疑问，请直接联系 ALK 总部或任何全球办事处的媒体关系部。

The press releases in this press room contains information that is of general news value for the press, and available for journalists or media with a view to journalistic assessment and preparation before publication.

News

See all
  • Post date
    08/14/2025
    Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025
    Read more
  • Post date
    08/12/2025
    ALK upgrades its full-year revenue outlook
    Read more
  • Post date
    07/21/2025
    ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system
    Read more
  • Post date
    07/18/2025
    EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
    Read more
  • Post date
    06/26/2025
    First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
    Read more
  • Post date
    06/16/2025
    ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025
    Read more
  • Post date
    06/04/2025
    ALK participates at Jefferies Global Healthcare Conference 2025 in New York
    Read more
  • Post date
    05/08/2025
    ITULATEK® approved for treatment of children and adolescents in Canada
    Read more
  • Post date
    05/06/2025
    Three-month interim report (Q1) 2025 (unaudited)
    Read more

媒体关系

投资者关系

Per Plotnikof

企业传播、

投资者关系和战略规划

副总裁

电话：+45 2261 2525

电子邮件：PPIDK@alk.net

 

媒体关系

Jeppe Ilkjær

企业传播

媒体关系经理

电话：+45 3050 2014

电子邮件：Jeppe.Ilkjaer@alk.net

公司简介
快速了解过敏症免疫治疗市场中的领导者 ALK 的概况
关键财务数据
阅读 ALK 的最新财务业绩
欢迎记者朋友随时联系 ALK 的媒体关系团队。

图片

查找各种可供下载的图片。
Steen Riisgaard, CEO
下载图片
Production facilities, Hørsholm
下载图片
alk_produktion6_0
Production facilities, Hørsholm
下载图片
alk_produktion3_1
Production facilities, Hørsholm
下载图片
alk_produktion5
Production facilities, Hørsholm
下载图片
Family_website_0
ALK HQ, Hørsholm
下载图片
Last updated: 2016.11.14